Enlivex Therapeutics Ltd. (ENLV)
NASDAQ: ENLV · Real-Time Price · USD
1.350
-0.040 (-2.88%)
Oct 31, 2024, 4:00 PM EDT - Market closed

Company Description

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.

Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis.

The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.

Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Enlivex Therapeutics Ltd.
Enlivex Therapeutics logo
Country Israel
Founded 2005
IPO Date Dec 12, 1995
Industry Biotechnology
Sector Healthcare
Employees 71
CEO Oren Hershkovitz

Contact Details

Address:
14 Einstein Street
Ness Ziona, 7403618
Israel
Phone 972 2 670 8072
Website enlivex.com

Stock Details

Ticker Symbol ENLV
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000919794
CUSIP Number M4130Y106
ISIN Number IL0011319527
Employer ID 95-4102687
SIC Code 7372

Key Executives

Name Position
Dr. Oren Hershkovitz Ph.D. Chief Executive Officer
Shai Novik M.B.A. Executive Chairman
Shachar Shlosberger CPA Chief Financial Officer
Veronique Amor-Baroukh Senior Director of Operations
Sigal Arad Director of Human Resources

Latest SEC Filings

Date Type Title
Oct 3, 2008 15-12G Securities registration termination
Oct 3, 2008 8-K Current Report
Oct 2, 2008 25-NSE Filing
Sep 25, 2008 8-K Current Report
Sep 25, 2008 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Sep 9, 2008 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Sep 9, 2008 425 Filing
Sep 5, 2008 8-K Current Report
Sep 5, 2008 425 Filing
Aug 27, 2008 425 Filing